Decoding the Shapeshifting Nature of Cancer Drug Resistance

Therapeutic resistance acts as a formidable barrier in oncology, frequently limiting the lifespan of treatments and leading to relapse. A systematic review now highlights that tumours are not static targets but dynamic ecosystems. They survive through a coordinated effort involving genetic alterations, epigenetic reprogramming, and metabolic shifts. Crucially, the review underscores the emerging role of the microbiome, which can influence therapeutic responses through immune modulation.

To combat this, scientists are moving towards strategies grounded in evolutionary principles. Rather than simply reacting, the aim is to predict how a tumour will adapt. New approaches include 'synthetic lethality'—exploiting the very mechanisms cancer uses to survive to kill it instead—and disrupting the supportive environments of stem cells. Advances in artificial intelligence and liquid biopsy are proving transformative, enabling the real-time detection of resistance as it evolves. By bridging the gap between molecular mechanics and clinical design, this roadmap offers hope for achieving sustained, long-term cancer control through better preclinical modelling and adaptive therapies.